The present invention relates to a controlled release device for oral cavity, which is attached on a hard dental surface of a tooth. The attachment is done using any adhesive layer that can attach on enamel surface of a tooth or using a holder attached to the hard dental surface, to which holder the device can be attached, clipped or fastened. The device comprises of two or more polymeric materials forming a polymer matrix or matrices. The polymer matrices incorporate one or more agent(s), which release rate in the oral cavity can be con-trolled with the polymeric materials in the matrices. The invention also relates to a method producing a controlled re-lease device for delivering an agent to the oral cavity.

Provided are methods and compositions for reducing a throat irritation caused by inhaling vapors or particles of at least one material selected from the group consisting of cannabis, cannabinoids, tobaccO, a herb or combinations thereof, the method comprising administering to a subject in need thereof at least one transient receptor potential (TRP) channel modulator prior to or simultaneously with said inhaling said vapors or particles of said at least one material. Further provided are methods and compositions comprising at least one TRP channel agonist, and/or at least one TRP channel partial agonist for treating pain-selective analgesia via TRP channels; methods for treating local pain; methods for treating migraine and symptoms thereof; and methods for treating osteoporosis and symptoms thereof.

Provided are methods and compositions for reducing a throat irritation caused by inhaling vapors or particles of at least one material selected from the group consisting of cannabis, cannabinoids, tobaccO, a herb or combinations thereof, the method comprising administering to a subject in need thereof at least one transient receptor potential (TRP) channel modulator prior to or simultaneously with said inhaling said vapors or particles of said at least one material. Further provided are methods and compositions comprising at least one TRP channel agonist, and/or at least one TRP channel partial agonist for treating pain-selective analgesia via TRP channels; methods for treating local pain; methods for treating migraine and symptoms thereof; and methods for treating osteoporosis and symptoms thereof.

Provided are methods and compositions for reducing a throat irritation caused by inhaling vapors or particles of at least one material selected from the group consisting of cannabis, cannabinoids, tobaccO, a herb or combinations thereof, the method comprising administering to a subject in need thereof at least one transient receptor potential (TRP) channel modulator prior to or simultaneously with said inhaling said vapors or particles of said at least one material. Further provided are methods and compositions comprising at least one TRP channel agonist, and/or at least one TRP channel partial agonist for treating pain-selective analgesia via TRP channels; methods for treating local pain; methods for treating migraine and symptoms thereof; and methods for treating osteoporosis and symptoms thereof.

An orally ingestible contraceptive composition for a pig is provided. The exemplary composition comprises 0.005 to 1.4 wt. % free gossypol and non-free-gossypol matter. The non-free-gossypol matter comprises a bulk feed component, a pig attractant, a flavored component or any combination thereof. In a second aspect, an assembly is provided. The assembly comprises an orally ingestible contraceptive composition for a pig and a package. In a third aspect, a system for delivering an orally ingestible contraceptive composition to a pig is provided. The system comprises the composition and an apparatus. The apparatus is configured to permit pigs to eat the composition and inhibit other animals from eating the composition. In a fourth aspect, a method is provided for delivering an orally ingestible contraceptive composition to a pig. The method comprises making the composition available to the pig.

An orally ingestible contraceptive composition for a pig is provided. The exemplary composition comprises 0.005 to 1.4 wt. % free gossypol and non-free-gossypol matter. The non-free-gossypol matter comprises a bulk feed component, a pig attractant, a flavored component or any combination thereof. In a second aspect, an assembly is provided. The assembly comprises an orally ingestible contraceptive composition for a pig and a package. In a third aspect, a system for delivering an orally ingestible contraceptive composition to a pig is provided. The system comprises the composition and an apparatus. The apparatus is configured to permit pigs to eat the composition and inhibit other animals from eating the composition. In a fourth aspect, a method is provided for delivering an orally ingestible contraceptive composition to a pig. The method comprises making the composition available to the pig.

Compositions and methods for treating administering retinoid or retinoid-related compounds without side effects.

Compositions and methods for treating administering retinoid or retinoid-related compounds without side effects.

Persistent inflammation is a driving force of fibrosis progression. Mucosal-Associated Invariant T (MAIT) cells are non-conventional T cells that display altered functions during chronic inflammatory diseases. Here, the inventors report a loss of circulating MAIT cells in cirrhotic patients and their hepatic accumulation in an activated phenotype within the fibrotic septa. Using two models of chronic liver injury, the inventors demonstrate that mice enriched in MAIT cells (Vα19TCRTg) show exacerbated liver fibrosis and higher number of hepatic fibrogenic cells than wild type counterparts, whereas MAIT cell-deficient mice (MR1.sup.−/−mice) are resistant. The results highlight the profibrogenic functions of MAIT cells and suggest that 1 targeting MAIT cells may constitute an attractive antifibrogenic strategy during chronic liver injury. Accordingly, the present invention relates to a method of treating fibrosis in a patient in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of inhibiting the activation of MAIT cells.

Persistent inflammation is a driving force of fibrosis progression. Mucosal-Associated Invariant T (MAIT) cells are non-conventional T cells that display altered functions during chronic inflammatory diseases. Here, the inventors report a loss of circulating MAIT cells in cirrhotic patients and their hepatic accumulation in an activated phenotype within the fibrotic septa. Using two models of chronic liver injury, the inventors demonstrate that mice enriched in MAIT cells (Vα19TCRTg) show exacerbated liver fibrosis and higher number of hepatic fibrogenic cells than wild type counterparts, whereas MAIT cell-deficient mice (MR1.sup.−/−mice) are resistant. The results highlight the profibrogenic functions of MAIT cells and suggest that 1 targeting MAIT cells may constitute an attractive antifibrogenic strategy during chronic liver injury. Accordingly, the present invention relates to a method of treating fibrosis in a patient in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of inhibiting the activation of MAIT cells.